Key result
Anti-inflammatory therapy, particularly colchicine added to baseline therapy, is a promising and safe strategy to prevent recurrent events in patients with CAD and acute MI.
Why the study?
This review aimed to investigate the potential use of anti-inflammatory drugs in patients with acute myocardial infarction and coronary artery disease.
Does adding anti-inflammatory therapy (such as colchicine) to baseline therapy prevent recurrent index events in patients with coronary artery disease and acute myocardial infarction?
Does adding anti-inflammatory therapy (such as colchicine) to baseline therapy prevent recurrent index events in patients with coronary artery disease and acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
This review highlights that assessing systemic inflammation (hsCRP) and adding anti-inflammatory therapy, especially colchicine, to baseline treatment is a justified and promising strategy to prevent recurrent events in patients with CAD and acute MI.
Aim: To investigate the potential use of anti-inflammatory drugs in patients with acute myocardial infarction (MI). Materials and Methods: A comprehensive search was conducted in the scientometric databases PubMed, Scopus, Web of Science, and Google Scholar for data from peer-reviewed English-language studies on the use of anti-inflammatory drugs in patients with coronary artery disease (CAD) published over the past 10 years. Results: Data from recent scientific studies indicate that the assessment of markers of systemic inflammation, particularly hsCRP, in patients with CAD is no less important than that of the lipid profile. The use of anti-inflammatory agents is an important component of prognosis-modifying therapy, especially in clinically complex patients who experience recurrent index events despite baseline therapy. Currently, the most well-studied anti-inflammatory agent with a sufficient safety profile in patients with CAD, including those with acute MI, is colchicine. Conclusions: Measuring levels of inflammatory markers and using anti-inflammatory agents, particularly colchicine, in addition to baseline therapy in patients with acute MI to prevent recurrent index events is justified and promising.
No takes yet. Share an insight, caveat, or question.
Savitska et al. (2026) conducted a review in Coronary artery disease (CAD) and acute myocardial infarction (MI). Anti-inflammatory agents (particularly colchicine) vs. Baseline therapy alone was evaluated on Prevention of recurrent index events. Anti-inflammatory therapy, particularly colchicine added to baseline therapy, is a promising and safe strategy to prevent recurrent events in patients with CAD and acute MI.
Synapse has enriched 10 related papers. Consider them for comparative context: